NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Forecast, Price & News

$5.67

+0.68 (+13.63%)

(As of 05/31/2023 ET)

Compare

Today's Range: $5.04
▼
$5.75
50-Day Range: $2.82
▼
$6.56
52-Week Range: $2.75
▼
$19.30

Volume: 200,800 shs
Average Volume: 123,494 shs
Market Capitalization: $57.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Carisma Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 58.7% Upside
$9.00 Price Target
Short Interest: Healthy
2.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.52) to ($1.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

480th out of 1,006 stocks

Pharmaceutical Preparations Industry

230th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Carisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Carisma Therapeutics has a forecasted upside of 58.7% from its current price of $5.67.
Amount of Analyst Coverage
Carisma Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.08% of the float of Carisma Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Carisma Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Carisma Therapeutics does not currently pay a dividend.
Dividend Growth
Carisma Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CARM.

3.3

News and Social Media Coverage

News Sentiment
Carisma Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Carisma Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.
MarketBeat Follows
5 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Carisma Therapeutics is held by insiders.
Percentage Held by Institutions
Only 16.45% of the stock of Carisma Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($2.52) to ($1.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Carisma Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Carisma Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Carisma Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Carisma Therapeutics (NASDAQ:CARM) Stock

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Stock News Headlines

May 31, 2023 | msn.com

Carisma Therapeutics Shines on New Cancer Treatment

May 30, 2023 | finance.yahoo.com

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

May 31, 2023 | Behind the Markets (Ad)

The 4th Military Revolution is Happening

. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>

May 26, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for Carisma Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CARM)

May 26, 2023 | americanbankingnews.com

Carisma Therapeutics, Inc. Forecasted to Post Q2 2023 Earnings of ($0.66) Per Share (NASDAQ:CARM)

May 24, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Carisma Therapeutics (CARM) with Buy Recommendation

May 24, 2023 | americanbankingnews.com

HC Wainwright Begins Coverage on Carisma Therapeutics (NASDAQ:CARM)

May 15, 2023 | markets.businessinsider.com

Carisma Therapeutics (CARM) Receives a Buy from Robert W. Baird

May 31, 2023 | Behind the Markets (Ad)

The 4th Military Revolution is Happening

May 14, 2023 | uk.investing.com

Carisma Therapeutics Inc (CARM)

May 14, 2023 | americanbankingnews.com

Carisma Therapeutics (CARM) vs. Its Peers Financial Contrast

May 11, 2023 | finanznachrichten.de

Carisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 11, 2023 | finance.yahoo.com

Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 8, 2023 | finance.yahoo.com

Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference

April 17, 2023 | americanbankingnews.com

Carisma Therapeutics (NASDAQ:CARM) Earns Outperform Rating from Analysts at Robert W. Baird

April 16, 2023 | americanbankingnews.com

Reviewing Cellectar Biosciences (NASDAQ:CLRB) and Carisma Therapeutics (NASDAQ:CARM)

April 14, 2023 | finance.yahoo.com

Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting

April 6, 2023 | finance.yahoo.com

Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023

April 4, 2023 | finanznachrichten.de

Carisma Therapeutics Inc.: Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights

April 4, 2023 | finance.yahoo.com

Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights

March 30, 2023 | thestreet.com

Carisma Therapeutics Inc.

March 20, 2023 | finance.yahoo.com

Carisma Therapeutics CEO Steven Kelly talks reverse merger, growth plans

March 15, 2023 | seekingalpha.com

CARM Carisma Therapeutics, Inc.

March 11, 2023 | benzinga.com

CARISMA Therapeutics Stock (NASDAQ:CARM), Earnings Estimates, EPS, and Revenue

March 11, 2023 | benzinga.com

CARISMA Therapeutics Stock (NASDAQ:CARM), Dividends

March 11, 2023 | benzinga.com

CARISMA Therapeutics Stock (NASDAQ:CARM), Guidance and Forecast

March 11, 2023 | benzinga.com

CARISMA Therapeutics Stock (NASDAQ:CARM), Analyst Ratings, Price Targets, Predictions

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Company Calendar

Last Earnings: 5/11/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CARM
CUSIP: N/A
CIK: 1485003
Web: N/A
Phone: 617-444-8550
Fax: 617-858-0911
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +100.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,880,000.00
Net Margins: N/A
Pretax Margin: -1,126.41%
Return on Equity: -9.52%
Return on Assets: -7.29%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 6.73
Quick Ratio: 6.73

Sales & Book Value

Annual Sales: $40 million
Price / Sales: 1.27
Cash Flow: $3.56 per share
Price / Cash Flow: 1.40
Book Value: $8.46 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 10,180,000
Free Float: 9,849,000
Market Cap: $50.80 million
Optionable: Not Optionable
Beta: 0.81

Key Executives

Steven Kelly
President, Chief Executive Officer & Director

Richard Steven Morris
CFO, Treasurer & Chief Compliance Officer

Michael Klichinsky
Chief Scientific Officer

Daniel J. Cushing
Chief Technology & Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CARM Stock - Frequently Asked Questions

Should I buy or sell Carisma Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARM shares.
View CARM analyst ratings or view top-rated stocks.
What is Carisma Therapeutics' stock price forecast for 2023?: 3 brokerages have issued 1 year price objectives for Carisma Therapeutics' shares. Their CARM share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 80.4% from the stock's current price.
View analysts price targets for CARM or view top-rated stocks among Wall Street analysts.
How have CARM shares performed in 2023?: Carisma Therapeutics' stock was trading at $3.25 on January 1st, 2023. Since then, CARM shares have increased by 53.5% and is now trading at $4.99.
View the best growth stocks for 2023 here.
When is Carisma Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CARM earnings forecast.
How were Carisma Therapeutics' earnings last quarter?: Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its earnings results on Thursday, May, 11th. The company reported ($1.93) earnings per share for the quarter. The company earned $3.24 million during the quarter.

What is Carisma Therapeutics' stock symbol?: Carisma Therapeutics trades on the NASDAQ under the ticker symbol "CARM."
Who are Carisma Therapeutics' major shareholders?: Carisma Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Group One Trading L.P. (0.00%), BML Capital Management LLC (4.04%), BlackRock Inc. (1.29%), Geode Capital Management LLC (1.17%), Susquehanna International Group LLP (0.00%) and Renaissance Technologies LLC (0.67%).
How do I buy shares of Carisma Therapeutics?: Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Carisma Therapeutics' stock price today?: One share of CARM stock can currently be purchased for approximately $4.99.
How much money does Carisma Therapeutics make?: Carisma Therapeutics (NASDAQ:CARM) has a market capitalization of $50.80 million and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis.
How can I contact Carisma Therapeutics?: Carisma Therapeutics' mailing address is 245 1st St Ste 1800, Cambridge, Massachusetts 02142-1292. The company can be reached via phone at 617-444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911.

This page (NASDAQ:CARM) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Carisma Therapeutics (CARM) Stock Forecast, Price & News

Carisma Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Carisma Therapeutics (NASDAQ:CARM) Stock

CARM Stock News Headlines

CARM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CARM Stock - Frequently Asked Questions

Overall MarketRank^™